STOCKHOLM, Feb. 22, 2019
STOCKHOLM, Feb. 22, 2019 /PRNewswire/ -- Summary of Q4
Financial overview October 1 – December 31, 2018
Significant events during the period October 1 to December 31, 2018
Significant events after the reporting period
Financial overview of the group
2018 Oct - Dec
2017 Oct - Dec
2018 Jan - Dec
2017 Jan - Dec
Loss before tax
Loss for the period
Earnings per share before and after dilution (SEK)
Cash flow from operating activities
Cash and cash equivalents at the end of the period
Research & development costs/operating expenses %
Conference call for investors, analysts and the media
The Year-end Report for 2018 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Friday February 22, 2019 at 14:00 (CET).
The conference call will also be streamed via a link on the website: www.oncopeptides.com.
Phone numbers for participants from:
Sweden: +46-8-566-427 06Europe: +44-3333-009-270 USA: +1-833-526-83-82
Annual Report 2018:
Week 17, 2019
Annual General Meeting:
May 21, 2019
Q1 Report 2019:
May 21, 2019
Q2 Report 2019:
July 12, 2019
Q3 Report 2019:
November 19, 2019
For more information, please contact:
Jakob Lindberg, CEO, Oncopeptides AB
Head of Investor Relations at OncopeptidesCell
This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on February 22, 2019.
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), a novel peptide conjugated alkylator that selectively targets multiple myeloma belonging to the class of peptide-enhanced compounds. Melflufen is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
More information is available on www.oncopeptides.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Year end report 2018 (PDF)
Press Release (PDF)